Humans and other metazoans have developed a symbiotic relationship with commensal 56 microbiota that provide enormous benefits to the host including vitamin synthesis, food 57 digestion, gut development, immunity and resistance to pathogenic infections (6, 18, 19, 63) . 58
Under normal conditions, approximately 10 14 bacteria made up of 300-1000 different species 59 inhabit the human gut (37). Dysbiosis is defined as dysregulation of the normal homeostasis of 60 the intestinal microbiota resulting in an imbalance of the number and composition of intestinal 61 microbes (15, 37) . Dysbiosis has been implicated in the pathogenesis of a myriad of disease 62 conditions, including antibiotic-associated diarrhea (AAD), Clostridia difficile-associated 63 disease, inflammatory bowel disease (IBD), metabolic syndrome, obesity, and cancer (3, 32, 33, 64 54, 59) . Over the past years, probiosis, prebiosis and fecal biotherapy have emerged as 65 therapeutic approaches for the prevention and treatment of dysbiosis-associated diseases (3, 22, 66 47, 50, 51) . Probiotics are live organisms that provide health benefits and mostly include 67
Lactobacillus species, Bifidobacterium species, E. coli, Saccharomyces boulardii and Trichuris 68 suis (10, 38, 50, 52, 53) . Although clinical trials of probiotics in some instances of dysbiosis 69 have shown promising results, the efficacy of these live organisms appears to be quite limited 70 and there is concern about occasional harmful side-effects (3, 5, 43, 46, 57) . 71
Prebiotics are defined as non-digestible food ingredients that promote the growth of 72 bacteria, stimulate host immunity, prevent pathogenic infections and facilitate host metabolism 73 and mineral absorption (10, 11, 13, 30, 47, 51, 52) . Some examples of prebiotics are: xylo-74 oligosaccharides, galacto-oligosaccharides, oligofructose, lactulose, inulin, and pomegranate 75 extracts (10, 11, 13, 27, 36, 51, 52, 55) . Prebiotics may be beneficial to healthy persons, but they 76 are not generally used in clinically ill patients (45, 60) . Up until now, an endogenous factor that 77 regulates the growth of a wide spectrum of gut bacteria has not been identified. 78 We have previously demonstrated that the brush-border enzyme intestinal alkaline 79 phosphatase (IAP) preserves the normal homeostasis of intestinal microbiota (37). We found that 80 compared to their wild-type (WT) littermates, IAP knockout (KO) mice harbor decreased 81 numbers of both aerobic and anaerobic bacteria. Furthermore, WT mice receiving oral IAP 82 supplementation and an antibiotic were found to rapidly restore the normal microbiota upon 83 termination of antibiotic treatment, thus reducing the antibiotic-induced susceptibility to enteric 84 pathogens such as Salmonella Typhimurium and Clostridium difficile (1). Based on the above 85 observations, we hypothesized that IAP functions as an endogenous bacterial growth-promoting 86 factor. In the present study we sought to delineate this role of IAP and to define its underlying 87 mechanisms of action. Here, we report that IAP is indeed an endogenous factor that 88 preferentially favors the growth of specific bacterial species, and furthermore, these effects occur 89 due to IAP-mediated reduction of the intestinal luminal concentrations of ATP and probably 90 other luminal nucleotide triphosphates. We believe that orally administered IAP could represent 91 a novel treatment against dysbiosis in humans. 92 93 7 no. 85e23 (National Institute of Health), revised 1985). The animal experimental protocols were 117 reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at MGH. 118
119
Bacterial culture. We observed that normal mouse stool does not contain any 120 streptomycin or ampicillin-resistant aerobic bacteria. Therefore, for our experiments, where we 121
wanted to use such bacteria in an intestinal loop model (see below) we selected representative 122
Gram-negative (Escherichia coli and Morganella morganii) and Gram-positive (Enterococcus 123
faecalis) bacteria from the normal gut flora and selected for streptomycin or ampicillin-124 resistance. Spontaneous streptomycin-resistant E. coli and M. morganii mutants were isolated by 125 culturing the bacterial sample in LB broth media containing streptomycin (100 μg/ml) followed 126 by sub-culturing the grown bacteria on MacConkey plates containing streptomycin (100 mg/ml). 127
Spontaneous mutations in the rpsL gene render the bacteria streptomycin-resistant and they are 128 phenotypically stable (24) . Similarly, ampicillin-resistant E. faecalis was acquired by growing 129 the native E. faecalis in a culture containing ampicillin. To ensure the absence of possible 130 contaminants, the phenotype of each bacterial species was confirmed by the Clinical Laboratory 131 of MGH. 132
Streptomycin-resistant Gram-negative bacteria (E. coli and M. morganii) were grown in 133 LB-broth and MacConkey-agar plates containing streptomycin (100 μg/ml). Similarly, 134 ampicillin-resistant bacteria (E. faecalis) were grown in LB-broth and LB-agar plates containing 135 ampicillin (100 μg/ml). For stool culture, mouse stool samples were collected fresh directly in 136 BHI media (500 μl) in a microfuge tube, kept on ice, and then vortexed to homogenize the 137 sample, followed by serial dilution and plating on LB-agar and Brucella (5% horse blood)-agar 138
plates. Plates were incubated in ambient air overnight at 37 o C for aerobic bacterial growth. For 139 8 anaerobic bacterial growth, plates were incubated in a sealed plastic bag containing CO 2 140 producing gas pack and anaerobic condition indicators (Fisher Scientific) for 3 days at 37 o C. 141
Samples were plated on the bench and then placed in the plastic bag. The color change of the 142 anaerobic indicator was strictly monitored. Colony forming units (CFU) were counted and 143 expressed as mean CFU +/-SEM. 144
The concentrations of IAP targets LPS, CpG DNA and flagellin used in bacterial cultures 145 were 10 μg/ml, 10 μg/ml and 100 ng/ml, respectively. Concentrations of ATP and other 146 nucleotides were 10 mM unless otherwise specified. In an experiment showing IAP-mediated 147 reversal of growth inhibitory effect of ATP (10 mM) on E. coli, Salmonella Typhimurium, 148
Staphylococcus aureus and Listeria monocytogenes, these bacteria were grown in LB-broth 149 containing 10 μl/ml (100 U/ml) of bovine IAP (Sigma) or 10 μl/ml 'vehicle for IAP' (50 mM 150
KCl, 10 mM Tris-HCl (pH 8.2), 1 mM MgCl 2 , 0.1 mM ZnCl 2 , and 50% glycerol, also known as 151 IAP storage buffer) (control group). All aerobic cultures (200 μl) were grown in 8 wells of a 96-152 well clear-bottom plate at 37 o C in a shaking incubator, and absorbance (OD 600 ) was determined 153 hourly or as indicated. Bacterial growth in a culture at a definite time-point was calculated as 154 average Absorbance (OD 600 ) +/-SD. 155
156
In vivo intestinal loop model. WT and IAP-KO mice (n = 5 per group unless indicated 157 otherwise) each weighing approximately 25 g were used. The procedure was done under general 158 anesthesia with inhalational isoflurane at 2% and 1 L/min maintenance flow of oxygen. After a 159 midline incision and exteriorization of the gut, a 5-cm segment of proximal jejunum, distal ileum 160 or colon was carefully tied off at the proximal and distal ends, thus constructing the loop. One 161 animal was used to construct only one loop. When indicated, mice (n = 5 per group) were fasted 162 for 14 h or 48 h to repress the expression of IAP as previously described (17) followed by 163 construction of the loop. Using a 28-G insulin needle, we injected (total of 100 μl) into the loop 164 approximately 1,000 colony forming units (CFU) of specific bacteria along with other reagents 165
[ATP (100 μM), IAP (100 U/ml), ARL 67156 (10 mM)] as indicated. The abdomen of the mouse 166 was closed and the bacteria were incubated in the isolated loop for 2 h, while the animal was still 167 under anesthesia. The loop was then harvested and the animal was sacrificed. The luminal 168 contents were squeezed off, loop was homogenized and both were plated on selective agar plates 169 and grown overnight at 37 o C. Bacterial growth was calculated as fold-increase i.e. the total 170 number of bacteria (CFU) in loop (luminal contents + luminal tissue) divided by the number of 171 instilled bacteria. 172
173
Intestinal alkaline phosphatase (IAP) assay. IAP activity was determined following the 174 protocol as previously described (37). Briefly, contents of a loop were collected by gentle 175 squeeze, centrifuged, and supernatant was collected. Twenty-five μl of the supernatant (or 176 aqueous IAP solution as a control) were mixed with 175 μl of phosphatase assay reagent 177 containing 5 mM of p-nitrophenyl phosphate (pNPP). Optical density at 405 nm was determined 178 approximately 10 min later when the reaction samples usually turned yellowish due to release of 179 p-nitrophenol. IAP activity is expressed as average units/ml sample +/-SEM. 180
181
Collection of intestinal luminal fluid. Mice were euthanized and the entire section of 182 intestine was dissected out. Luminal contents were collected by gentle squeezing and then 183 centrifuged at 13,000 x g to pellet the debris and bacteria. IAP-KO jejunal loop (approximately 1.5-fold differences in growth, p < 0.001 for both species). 214 Similar to the results with these Gram-negative species, the growth of E. faecalis, a native Gram-215 positive inhabitant of the gut, was also significantly higher in the WT compared to IAP-KO mice 216 ( Figure 1C Figure 1E ). 230
We next investigated the effects of inactivating the endogenous IAP enzyme via 231 treatment with oral L-phenylalanine (Phe) (14). Prior to isolating the intestinal loop, mice 232 received 10 mM L-Phe in their drinking water for 48 h. Compared to the mice receiving no Phe, 233 E. coli growth was significantly reduced in the jejunal loop of mice receiving Phe (2.61±0.10 vs. 234 1.53±0.12 fold increase, respectively; p < 0.001) ( Figure 1F ). Similar reduction of E. coli growth 235 was observed in the ileal loop (2.72±0.14 vs. 1.53±0.07 fold increase, respectively; p < 0.001) 236
( Figure 1G ), as well as in the colonic loop (2.65±0.12 vs. 1.74±0.07 fold increase, respectively; p 237 < 0.001) ( Figure 1H ). In order to further confirm the role of the IAP enzyme we next instilled 238 exogenous IAP into a jejunal loop of IAP-KO mice. We added 100 U of IAP or the vehicle 239 control along with the bacteria into a jejunal loop of IAP-KO mice. As predicted, we observed a 240 significant increase in E. coli growth when exogenous IAP was added to the intestinal loop 241 (2.61±0.12 vs. 1.63±0.07 fold increase, respectively; p < 0.001) ( Figure 1I We have previously shown that IAP does not directly affect the growth of bacteria (37) and 247 therefore, we hypothesized that IAP must exert its effects through some indirect mechanism, 248 likely by modulating one or more of its known target molecules within the luminal fluid. To 249 determine whether the luminal fluid itself is capable of promoting bacterial growth we examined 250 the bacterial growth in vitro upon incubation with luminal fluids from WT and IAP-KO mice. 251
The mice were euthanized and luminal fluid from the entire small intestine was gently squeezed 252 out and collected. E. coli bacteria were then added to the luminal fluid and incubated for 2 h at 253 37 o C. Figure 1J shows that E. coli growth was approximately two-fold higher in the luminal fluid 254 obtained from WT compared to IAP-KO mice. We then collected luminal fluids from proximal 255 small intestine (PSI), distal small intestine (DSI) and colon, and tested the growth of E. coli 256 ( Figure 1K ) and Salmonella Typhimurium ( Figure 1L Figure 2A shows that LPS (10 μg/ml), CpG DNA (10 μg/ml) and 266 flagellin (10 ng/ml) had no effect on the growth of aerobic stool bacteria. However, 10 mM ATP 267 caused an approximate 50% reduction in bacterial growth. ATP significantly attenuated bacterial 268 growth (repeated measures ANOVA: effect of time: F (5, 30) = 127.09, P value < 0.001; between 269 groups differences: F (4, 36) = 3.99, P value < 0.01; interaction of time and group: F (20, 132) = 1.58, P 270 value = 0.07; Tukey's post hoc test: P value < 0.05). Bacterial growth at the final time point is 271 depicted in Figure 2B . 272
We then determined the dose-effects of ATP on a lower inoculum of stool aerobic 273 bacteria and found that ATP inhibited growth even at lower concentrations and such inhibition 274 was dose-dependent (repeated measures ANOVA: effect of time: F (3, 68) = 586.91, P value < 275 0.001; P value < 0.001; interaction of time and group: F (27, 210) = 4.53, P value < 0.001; Tukey's 276 post hoc test: P value < 0.001 for 400, 800, 1600 µM of ATP) ( Figure 2C ). The highest effect of 277 ATP on bacterial growth was evident after 8 hours of incubation ( Figure 2D ). As expected, we 278 also observed the dose-dependent inhibitory effect of higher concentrations (mM) of ATP on the 279 growth of higher inoculum of stool aerobic bacteria (data not shown). 280
We next determined the effects of ATP derivatives on the stool aerobic bacterial growth. 281
The ATP derivatives ADP, AMP and phosphate exerted little or no inhibition on the growth of 282 the intestinal aerobic flora ( Figure 2E-F) . We also investigated the effects of the ATP derivative 283 adenosine and observed that adenosine has no effect on stool bacterial growth (data not shown). 284 IAP reverses the inhibitory effect of ATP on aerobic bacterial growth. The above data 285 established that ATP can inhibit the growth of mouse stool aerobic bacteria in vitro. We next 286 studied whether IAP would be able to reverse these inhibitory effects of ATP, and found that, 287 indeed, IAP is able to reverse the effects of ATP (10 mM) in a dose-dependent manner (repeated 288 measures ANOVA: effect of time: F (2, 77) = 287.97, P value < 0.001; between groups differences: 289 F (5, 78) = 5.10, P value < 0.001; interaction of time and group: F (10, 156) = 15.21, P value < 0.001; 290
Tukey's post hoc test: P value < 0.05 for 50 U/ml of IAP and P values < 0.01 for 100 and 200 291 U/ml of IAP) ( Figure 2G -H). These data suggest that IAP may exert its growth promoting effects 292 by blocking the growth inhibitory effects of its target molecule ATP. 293
294
ATP inhibits the growth of stool anaerobic bacteria in vitro. The aerobic bacterial 295 population represents only a minor portion of the total gut bacterial population, most of which is 296
anaerobic. Therefore, we sought to determine the effects of ATP and other IAP targets on the 297 growth of mouse stool anaerobic bacteria. We grew the stool bacteria in the presence of ATP (10 298 mM), LPS (10 μg/ml), CpG DNA (10 μg/ml) or flagellin (100 ng/ml) under anaerobic conditions 299 for 72 h at 37 o C. In a manner similar to aerobes, we found that the growth of anaerobes was 300 specifically inhibited by ATP (p < 0.01), whereas other IAP targets had no impact on the bacteria 301 ( Figure 3A) . 302
We then determined the dose response effects of ATP ( Figure 3B ) and found that the 303 anaerobes were particularly sensitive to the inhibitory effects of ATP (p < 0.001). We found that 304 100 μM ATP caused 50% inhibition of anaerobic bacterial growth ( Figure 3B ), whereas 1.2 mM 305 ATP completely inhibited the bacterial growth and higher concentrations of ATP killed these 306 bacteria (data not shown). We next investigated the effects of the ATP derivatives ADP, AMP, 307 and phosphate on the growth of these anaerobes and found that, like aerobes, the ATP 308 derivatives at 10 mM concentration did not have any significant impact on the growth of stool 309 anaerobic bacteria ( Figure 3C 
326
ATP differentially inhibits the growth of specific bacteria. We were interested to know 327 whether the growth-inhibitory effects of ATP were similar for all bacterial species. Accordingly, 328
we exposed 2 Gram-positive and 2 Gram-negative bacterial species to different concentrations of 329 ATP (1-20 mM). We observed that ATP slightly inhibited the growth of the Gram-negative 330 species E. coli ( Figure 5A ) and S. Typhimurium ( Figure 5B ), but had more profound inhibition 331 on the growth of the Gram-positive species, S. aureus ( Figure 5C Figure 7C shows that compared to WT jejunal loop, ATP concentration 363 was approximately 4.3-fold higher in the IAP-KO jejunal loop. We next directly tested whether 364 IAP destroys ATP in vivo. We instilled 100 U IAP into the jejunal loop in IAP-KO mice and 365 observed that compared to the control animals receiving no IAP, the ATP concentration was 366 significantly lower in the mice receiving IAP (approximately 80% reduction) ( Figure 7D ). 367
We next sought to determine whether exogenous ATP would inhibit bacterial growth 368 within the context of the intact gut luminal environment. To prevent the destruction of 369 exogenous ATP by the endogenous IAP, we fed WT mice 10 mM Phe in the drinking water for 370 48 h. We then instilled 100 μM ATP in the loop followed by E. coli. We observed that compared 371 to control mice receiving no ATP, E. coli growth was significantly lower in mice receiving ATP 372 (1.57±0.07 vs. 1.12±0.05, respectively; p < 0.001) ( Figure 7E ). To independently confirm this 373 inhibitory effect of ATP on bacterial growth in vivo, we instilled into the loop an ecto-ATPase 374 inhibitor ARL 67156 (10 mM), which is known to increase the ATP levels by inhibiting its 375 hydrolysis by ecto-ATPases of CD39 family (31). Again, we observed that compared to mice 376 receiving no ARL 67156, mice receiving ARL 67156 had a significant decrease in bacterial 377 growth (2.71±0.10 vs. 1.68±0.06, respectively; p < 0.001) ( Figure 7F ). Taken together, these 378 data indicate that ATP inhibits bacterial growth in vivo and that IAP exerts its growth promoting 379 effects by hydrolyzing ATP and probably other nucleotide triphosphates. 380
It has become clear in recent decades that intestinal dysbiosis plays a critical role in the 383 pathogenesis of many diseases (3, 32, 33, 54, 59) . A variety of different factors can be 384 responsible for dysbiosis and include antibiotics, psychological and physical stress, diets rich in 385 protein, simple sugar/refined carbohydrates, fat, or fructose, chemotherapy, radiation treatment, 386 and intestinal infections (7, 15, 16, 42) . Probiotics, prebiotics, synbiotics and fecal biotherapy 387 have emerged as therapies against dysbiosis, albeit with limited success (3, 22, 47, 50, 51) . 388
Prebiotics are known to modify and enhance the gut functionality, (10, 11, 13, 30, 47, 48, 52 ) 389 exerting their health benefits via alterations in the composition and/or activity of the intestinal 390 microbiota. In the present study we provide evidence that the brush-border enzyme intestinal 391 alkaline phosphatase (IAP) promotes the growth of commensal bacteria. IAP exerts a number of 392 beneficial effects on the gut, including the maintenance of local gut immunity (8) Typhimurium, S. aureus or L. monocytogenes (37). This observation led us to hypothesize that 407 IAP must work through an indirect mechanism, likely by blocking one or more of its target 408 molecules that otherwise inhibits bacterial growth (37). Accordingly, we tested the effects of 409 known IAP targets and found that only ATP to exhibit an inhibitory impact on bacterial growth. 410
More importantly, these effects of ATP were completely blocked after incubation with IAP, 411 WT littermates (41). Furthermore, IAP has been found to act as a gut mucosal defense factor and 438 its expression is influenced by exposure to bacteria (4, 14, 25) . IAP is also involved in the 439 maintenance of normal gut barrier function (12, 21) . 440
Pharmacologically, IAP has been found to be an effective therapy against various human 441 as well as animal disease models including IBD, necrotizing enterocolitis, gram-negative sepsis, 442 C. difficile and S. Typhimurium infections, and metabolic syndrome (1, 21, 34, 44, 56, 58, 61) . 443
Clinical trials using bovine IAP against colitis have shown that IAP has no or minimal side-444 effects (34). 445
Recently, we have shown that oral supplementation with IAP prevents high fat diet-446 associated metabolic syndrome in mice (21). We postulated that IAP detoxifies luminal 447 lipopolysaccharides (LPS) and therefore less LPS is available to be bound to fatty acids 448 (chylomicron) and be translocated to systemic circulation thus preventing metabolic 449 endotoxemia and consequently the metabolic syndrome. However, it is also possible that more 450 chronic alterations in the flora and/or levels of the extracellular nucleotide triphosphates caused 451 by IAP contribute to the prevention of obesity and the metabolic syndrome. 452
Here we show that the luminal ATP and other nucleotide triphosphates play a critical role 453 in preventing the bacterial growth. It is likely that the nucleotide triphosphates represent just one 454 factor in the overall regulation of the commensal bacterial population within the gut, working in 455 concert with other endogenous factors, e.g., antibacterial peptides (29, 49). The idea that 456 extracellular nucleotide triphosphates inhibit bacterial growth in the intestine raises the question 457 of whether these molecules play a similar role in other sites, e.g., the mouth, vagina, urinary and 458 respiratory tracts. Some associations have been noted between ATP and certain urinary and 459 respiratory infections (28, 35), but a role in terms of regulating bacterial growth has not been 460 previously reported. 461
In addition to the intestinal AP, mammalians express other AP forms, including placental, 462 germ cell, neutrophil, and tissue non-specific (liver/bone/kidney) (25). Furthermore, within the 463 mouse intestine, three different IAP isozymes exist (Akp3, 5, and 6). All of the AP enzymes 464 share significant structural homology as well as functional similarities, but it will be of interest in 465 the future to determine whether these other forms of AP also have the capability to promote 466 bacterial growth. ATP is also a known target of ecto-ATPases (23), which would be expected to 467 be intact in the IAP-KO mice. As ATP concentrations are increased in IAP-KO mice, it could be 468 concluded that ecto-ATPases are less efficient than IAP in destroying/inactivating ATP. Further 469 work will be needed to determine whether other ecto-nucleotidases play any role in regard to 470 regulating the gut microflora. 471
In conclusion, although caution should always be taken extrapolating mouse studies to 472 humans, the present data indicate that IAP functions as an endogenous promoter of commensal 473 bacterial growth, likely through an inhibition of luminal ATP and other nucleotide triphosphates. 474
As such, we believe that these findings lay the groundwork for developing IAP-based therapies 475 in clinical settings of dysbiosis, either as a supplement or through a diet-related increase in 476 endogenous levels. The concept of using an endogenous enzyme as a supplement to promote 477 commensal bacteria is not only novel, but could also represent a simple and safe way to impact 478 significance between two groups was tested using the two-tailed Student's t test.; *p < 0.05, **p 712 < 0.01, ***p < 0.001. 
